Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data

被引:0
|
作者
Hong Ki Min [1 ]
Se Hee Kim [1 ]
Jong Han Choi [1 ]
Kyomin Choi [2 ]
Hae-Rim Kim [3 ]
Sang-Heon Lee [3 ]
机构
[1] Department of Internal Medicine, Konkuk University Medical Center
[2] Department of Neurology, Konkuk University Medical Center
[3] Division of Rheumatology, Department of Internal Medicine,Konkuk University School of Medicine
关键词
D O I
暂无
中图分类号
R587.2 [糖尿病性昏迷及其他并发症];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Neuropathy is a common chronic complication in type 2 diabetes mellitus(T2DM). Statin and metformin are commonly used medications in T2DM patients, and some studies showed statin-or metformin-induced neuropathy.AIM To evaluate the incidence of neuropathy among patients with T2DM associated with statin and metformin therapies.METHODS Korean Health Insurance Review and Assessment national patient sample data from 2016 and 2017 were used. Patients with T2 DM and no complications were divided into statin/metformin/statin + metformin users and non-users. Neuropathy incidence was defined by International Statistical Classification of Diseases and Related Health Problems, 10 th revision codes and concomitant prescriptions for anticonvulsants or antidepressants. Logistic regression analyses were conducted to examine the associations between statin/metformin/statin + metformin therapies and the incidence of neuropathy. Propensity score(PS) matching was performed on the basis of age, sex and comorbidities.RESULTS Overall, 34964 and 35887 patients with T2DM and no complications were included in the Korean Health Insurance Review and Assessment national patient sample datasets from 2016 and 2017, respectively. Statin therapy was associated with increased risks of neuropathy in 2016 and 2017 [PS-matched odds ratio(OR) = 1.22, 95% confidence interval(CI): 1.08-1.38; PS-matched OR = 1.17, 95%CI: 1.03-1.33, respectively]. Metformin therapy was associated with reduced risks of neuropathy in 2016 and 2017(PS-matched OR = 0.30, 95%CI: 0.21-0.42; PSmatched OR = 0.44, 95%CI: 0.32-0.60, respectively). Combined statin + metformin therapy was not significantly associated with neuropathy in 2016 or 2017(PSmatched OR = 0.85, 95%CI: 0.61-1.19; PS-matched OR = 0.95, 95%CI: 0.66-1.38, respectively).CONCLUSION Statin therapy was associated with enhanced risk of new-onset neuropathy in patients with T2DM, but metformin therapy showed the opposite association.
引用
收藏
页码:10198 / 10207
页数:10
相关论文
共 50 条
  • [41] Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus
    Feher, Michael
    Greener, Mark
    Munro, Neil
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2013, 6 : 11 - 15
  • [42] The characteristics of Korean type 2 diabetes mellitus(DM) patients with inflammation
    Ryu, Hankyoung
    Park, Heejung
    Lee, Eunhee
    Huh, Kapbum
    Choi, Youngju
    Kim, Whayoung
    FASEB JOURNAL, 2007, 21 (06): : A1056 - A1056
  • [43] The prevalence of peripheral and autonomic neuropathy in patients with type 2 diabetes mellitus in a diabetes clinic
    Domeisen, U
    Schwegler, B
    Spinas, GA
    Lehmann, R
    DIABETES, 2002, 51 : A519 - A519
  • [44] Advantages of Extended-Release Metformin in Patients with Type 2 Diabetes Mellitus
    Jabbour, Serge
    Ziring, Barry
    POSTGRADUATE MEDICINE, 2011, 123 (01) : 15 - 23
  • [45] Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus
    Tseng, Chin-Hsiao
    AGING-US, 2016, 8 (08): : 1636 - 1649
  • [46] Metformin and risk of developing nasopharyngeal cancer in patients with type 2 diabetes mellitus
    Tseng, Chin-Hsiao
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2018, 85 : 223 - 226
  • [47] Antioxidant effects of gliclazide, glibenclamide, and metformin in patients with type 2 diabetes mellitus
    Signorini, AM
    Fondelli, C
    Renzoni, E
    Puccetti, C
    Gragnoli, G
    Giorgi, G
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2002, 63 (07): : 411 - 420
  • [48] Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension
    Uehara, MH
    Kohlmann, NEB
    Zanella, MT
    Ferreira, SRG
    DIABETES OBESITY & METABOLISM, 2001, 3 (05): : 319 - 325
  • [49] Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated
    Irons, Brian K.
    Minze, Molly G.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2014, 7 : 15 - 24
  • [50] The effect of metformin on the survival of colorectal cancer patients with type 2 diabetes mellitus
    Zeinab Tarhini
    Kamelia Manceur
    Julien Magne
    Muriel Mathonnet
    Jeremy Jost
    Niki Christou
    Scientific Reports, 12